Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1295-1301 , December 2006

Safety and Efficacy of Donor Lymphocyte Infusions following Mismatched Stem Cell Transplantation

Received 28 March 2006 ,Accepted 29 July 2006.

References 

  1. Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation. 1995;60:778–783
  2. Beatty PG, Boucher KM, Mori M, Milford EL. Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Hum Immunol. 2000;61:834–840
  3. Slavin S, Or R, Naparstek E, et al. Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders. Transplant Proc. 1987;19:2614–2615
  4. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-vs-host disease in human recipients of marrow from HLA-matched-sibling donors. Transplantation. 1974;18:295–304
  5. Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant. 1996;17:273–275
  6. Nakamura Y, Leppert M, O’Connell P, et al. Variable number of tandem repeats (VNTR) markets for human gene mapping. Science. 1987;235:1616–1622
  7. Johnson PR, Hersey P. Anti-leukaemia activity as a bystander effect of graft-versus-host reactions. Br J Cancer. 1976;33:370–378
  8. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–1073
  9. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529–1533
  10. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23:1553–1562
  11. Kolb HJ, Schattenberg A, Goldman JM, et al. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  12. Raiola AM, Van Lint MT, Valbonesi M, et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant. 2003;31:687–693
  13. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–444
  14. Kawano Y, Takaue Y, Watanabe A, et al. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor. Blood. 1998;92:3123–3130
  15. Klingebiel T, Handgretinger R, Lang P, Bader P, Niethammer D. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev. 2004;18:181–192
  16. Lee CK, deMagalhaes-Silverman M, Hohl RJ, et al. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. Bone Marrow Transplant. 2003;31:121–128
  17. Diez-Martin JL, Gomez-Pineda A, Serrano D, Carrion R, Balsalobre P, Buno I. Successful treatment of incipient graft rejection with donor leukocyte infusions, further proof of a graft versus host lymphohaemopoietic effect. Bone Marrow Transplant. 2004;33:1037–1041
  18. Wu BY, Guo KY, Song CY, Yang DA, Li D. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000;26:691–693
  19. Pati AR, Godder K, Lamb L, Gee A, Henslee-Downey PJ. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 1995;15:979–981
  20. Naparstek E, Or R, Nagler A, et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor’s peripheral blood lymphocytes for prevention of relapse. Br J Haematol. 1995;89:506–515
  21. Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies. Clinical Transplants. 1996;Volume 12:281–290
  22. Wang J, Shaw JL, Mullen CA. Down-regulation of antihost alloreactivity after bone marrow transplant permits relapse of hematological malignancy. Cancer Res. 2002;62:208–212
  23. Kleinclauss F, Perruche S, Masson E, et al. Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion. Cell Death Differ. 2006;13:41–52
  24. Raanani P, Dazzi F, Sohal J, et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 1997;99:945–950
  25. Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S. Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J Immunother. 2001;24:114–121
  26. Slavin S, Ackerstein A, Morecki S, Gelfand Y, Cividalli G. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigens pulsed donor lymphocytes. Bone Marrow Transplant. 2001;28:795–798
  27. Slavin S, Shapira M, Morecki S, et al. American Society of Clinical Oncology (ASCO) Use of matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ for immunotherapy of resistant leukemia after allogeneic stem cell transplantation. New Orleans, Louisiana, USA. June 3-8, 2004 Am Soc Clin Oncol. 2004;23:560;Abstract 6516
  28. Falkenburg JHF, Faber LM, van den Elshout M, et al. Generation of donor derived antileukemic cytotoxic T lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA identical bone marrow transplantation. J Immunother. 1993;14:305–309
  29. Slavin S, Shapira MY, Morecki S, et al. Immunotherapy for resistant hematologic malignancies using matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ after allogeneic stem cell transplantation for allogeneic cell therapy without GVHD. Blood. 2003;102:400b;Abstract 5329
  30. Ackerstein A, Morecki S, Gelfand Y, Samuel S, Or R, Slavin S. Outpatient non-myeloablative cell-mediated immunotherapy with intentionally mismatched allogeneic lymphocytes with rIL-2 for patients with metastatic solid tumors. Blood. 2003;102:409b;Abstract 5366
  31. Weiss L, Reich S, Slavin S. The role of non-activated and rIL-2 activated CD4+ and CD8+ T cells in immunotherapy for leukemia. Cytokines Cell Mol Ther. 1999;5:153–158
  32. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333–339
  33. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood. 2006;107:1564–1569

PII: S1083-8791(06)00519-2

doi: 10.1016/j.bbmt.2006.07.014

Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1295-1301 , December 2006

Article Tools

* Image Usage & Resolution